Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)

NCT03713684 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT03713684
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03713684 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 56-week, Multicenter, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of Efpeglenatide Once Weekly in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Basal Insulin Alone or in Combination With Oral Antidiabetic Drug(s)
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Terminated
Start date
November 9, 2018
Completion date
January 4, 2021
Enrollment
370 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus